Stephanie is an Investment Manager at Artesian Alternative Investments and also consultant at Eresm Consulting.
She has extensive experience in commercialisation of deep tech, especially in the health and medical sector, with expertise across early stage translation, licensing and spin-out formation through to leading seed-series B venture capital investments.
Prior to joining Artesian, Stephanie worked as Director of Innovation & Translation at MTPConnect, and spent over 5 years at Imperial College London first as Director of Industry Partnerships & Commercialisation, Medicine and later as an expert consultant. She also supported the development of TenU's USIT Guide and USIT for Software Guide - recommendations for negotiating investment deals and what a positive deal should look like for the Innovation Sector.
Stephanie holds a MBA from the University of South Australia, is a Graduate of the Australian Institute of Company Directors, a Certified Licensing Professional and has graduate qualifications in both Business and Biomedical Science. She currently serves on the board of BiomeBank and Ferronova and previously served as Deputy Chair for Cure4CF Foundation